SCHEMBL5504181

SCHEMBL5504181

COc1cc(/C=C2\SC(=O)NC2=O)ccc1OCc1cccc(F)c1

nearest known ligand 0.79

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.79
KMT2A Q03164 6/20 0.79
IGF1R P08069 1/20 0.66
CISD1 Q9NZ45 2/20 0.66
PIM1 P11309 2/20 0.64
PIM2 Q9P1W9 2/20 0.64
PDE4B Q07343 1/20 0.64
PIM3 Q86V86 1/20 0.64
ALDH1A1 P00352 1/20 0.60
LMNA P02545 1/20 0.60
PABPC1 P11940 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
PTPN1 P18031 3/20 0.59
HPGD P15428 2/20 0.59
ADAMTS5 Q9UNA0 2/20 0.59
MGAM O43451 1/20 0.59
GAA P10253 1/20 0.59
SI P14410 1/20 0.59
MGAM2 Q2M2H8 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5504182 1.00 MEN1 (0.79) MEN1KMT2AIGF1RCISD1PIM1
SCHEMBL5508719 0.88 MEN1 (1.00) MEN1KMT2AIGF1RCISD1PIM1
SCHEMBL5508722 0.88 MEN1 (1.00) MEN1KMT2AIGF1RCISD1PIM1
SCHEMBL5509658 0.82 MEN1 (0.64) MEN1KMT2AIGF1RCISD1PIM1
SCHEMBL5509654 0.82 MEN1 (0.64) MEN1KMT2AIGF1RCISD1PIM1
SCHEMBL1249272 0.81 MEN1 (0.87) MEN1KMT2ACISD1ALDH1A1PTPN1
SCHEMBL1249271 0.81 MEN1 (0.87) MEN1KMT2ACISD1ALDH1A1PTPN1
SCHEMBL4053367 0.80 CISD1 (0.83) MEN1KMT2ACISD1PDE4BALDH1A1
SCHEMBL4053371 0.80 CISD1 (0.83) MEN1KMT2ACISD1PDE4BALDH1A1
SCHEMBL15421515 0.80 PDE4B (1.00) MEN1KMT2AIGF1RPIM1PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781271-A1 ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-09 EP claimed
WO-2006019741-A1 ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2006-02-23 WO claimed
US-20060014812-A1 Use of estrogen related receptor-modulating aryl ethers JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-19 US claimed
EP-1781271-A1 ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-09 EP disclosed
WO-2006019741-A1 ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2006-02-23 WO disclosed
WO-2006019741-A1 ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2006-02-23 WO disclosed
US-20060014812-A1 Use of estrogen related receptor-modulating aryl ethers JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014812-A1 Use of estrogen related receptor-modulating aryl ethers ESR2, ESRRG, GPER1 MEN1 4702/4885KMT2A 1285/4885IGF1R 931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.